GoldenGolden
Adverum Biotechnologies

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

Funding
Venture round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.

Series B

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

Venture round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

Timeline

May 7, 2016
Merger of Avalanche Biotechnologies and Annapurna Therapeutics

The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

September 19, 2014
Venture funding round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

September 2014
Adverum Biotechnologies raises a $10,000,000 venture round.
April 22, 2014
Series B funding round

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

April 2014
Adverum Biotechnologies raises a $55,000,000 series B round from Adage Capital Management, Deerfield Management Company, Redmile Group, Rock Springs Capital, Sabby Capital and Venrock.
November 2, 2013
Venture funding round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investor

November 2013
Adverum Biotechnologies raises a $5,700,000 venture round.
July 25, 2006
Adverum Biotechnologies was founded by Mark S. Blumenkranz and Mitchell H. Finer.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Adverum Biotechnologies Series B round, April 2014
55,000,000
April 2014
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Mark S. Blumenkranz

Co-Founder

Carla Fiankan

Vice President, Regulatory Affairs

Claire Gelfman

Executive Director, Pharmaceutical Development

Jennifer Cheng

Vice President and General Council

Leone Patterson

CEO, Director, and CFO

Mehdi Gasmi

President and CSO

Michael Steel

Vice President, Quality

Mike Fitzgerald

Vice President , Human Resources

Mitchell H. Finer

Co-Founder

Pratik Jaluria

Executive Director, Process Development and Manufacturing

Steven D. Schwartz

Co-Founder

Thomas W. Chalberg

Co-Founder

Further reading

Title
Author
Link
Type
Date

Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today

Maxx Chatsko

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
April 29, 2021
FierceBiotech
Adverum saw its shares down more than 51% after-hours Wednesday night after a patient it was testing a gene therapy on for a common eye condition went blind in the treated eye.
BioSpace
April 22, 2021
BioSpace
Urges Stockholders to Vote the WHITE Proxy Card "FOR" ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
The Sonic Fund II, L.P.
April 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc....
BioSpace
November 14, 2020
BioSpace
Company to host webcast with Key Opinion Leaders to discuss new OPTIC data today, Saturday, November 14, 2020 at 7:30 am PT / 10:30 am ET

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.